Diamond Pharma Services Ltd (Diamond), a leading technical services and regulatory affairs consulting group, providing expert support and advice to pharmaceutical and biotechnology companies, has received the award for Best Specialist CRO at the Oxford Bioscience Network (OBN) Awards, in recognition of the Companys expert services in cell and gene therapy.
The OBN Awards, which are celebrating their 10th anniversary, are one of the UK life science industrys most prestigious awards evenings, reported a record increase in entry numbers, with entries up an impressive 48% on last years total. Over 300 delegates attended the event, which recognise the most inspiring and innovative UK-based companies across biotech, medtech, imaging, digital and synthetic biology. The Awards took place at the Oxford Examination Schools, an historical Grade II listed venue.
Diamond provides high quality strategic and operational services to the pharmaceutical and biotechnology industry. Within the cell and gene therapy field, Diamonds services and expertise cover all stages of development, including support for engagement with regulatory authorities, dossier writing, scientific advice meetings, orphan designations, paediatric investigation plans, clinical trial applications, GMO applications, and the coordination and leadership for Marketing Authorisation applications within the EU. The development of cell and gene therapies through to market is particularly challenging due to the regulatory framework, the novelty of the products, the unusual mechanism of action, and because the indications are typically very rare diseases.
Earlier this year Diamond announced that it supported Kite Pharma Inc in securing positive CHMP opinion for its breakthrough CAR-T cell cancer therapy, YESCARTA. The regulatory team within Diamond Pharma Services supported in all European regulatory activities throughout the development, submission, and Regulatory Authority review of the Marketing Authorisation Application. Diamond also played an integral part in the European regulatory approval of the first gene therapy product, Glybera, in 2012.
Maureen Graham, Managing Director, Regulatory, Diamond Pharma Services, said: The outcome of last nights Awards is testament to the hard work and dedication of the team at Diamond Pharma Services. To be recognised for our expertise, as well as the valuable role our cell and gene therapy services have played in the success of two of the most high profile products in this innovative area, is a huge honour.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
For further information about Diamond Pharma Services visit https://www.diamondpharmaservices.com/
For further information and high-resolution images:
Communications for Diamond Pharma Services
+44 7811 996 942
E-mail: [email protected]